8-K: Beyond Air Secures European CE Mark for LungFit PH System, Triggering $1 Million Milestone Payment

Beyond Air has received European CE mark approval for its LungFit PH system, allowing sales in the EU and other regions and triggering a $1 million milestone payment.

Summary

• Beyond Air has obtained CE mark approval for its LungFit PH system, which allows the company to market the device in the European Union and other countries recognizing the certification.
• The LungFit PH system is the first device in the LungFit therapeutic platform and uses patented Ionizer technology to generate nitric oxide from ambient air.
• The CE mark approval triggers a $1 million milestone payment from Beyond Air's Asia-Pacific partner, Getz Healthcare.
• Beyond Air will also receive ongoing royalty payments based on LungFit PH net sales from Getz Healthcare.
• The LungFit PH system is indicated for the treatment of infants with hypoxic respiratory failure and for periand post-operative pulmonary hypertension in conjunction with heart surgery.
• The device delivers nitric oxide at a dosage consistent with the current standard of care, ranging from 0.5 ppm to 80 ppm.
• The LungFit PH system is designed to be energy-efficient, using power equivalent to a 60-watt light bulb, and eliminates the need for nitric oxide tanks or chemicals.

Sentiment

Score: 9

Explanation: The document conveys a very positive sentiment due to the successful CE mark approval, the milestone payment, and the potential for future revenue growth. The company is clearly making progress in its commercialization efforts.

Positives

• The CE mark approval opens up the European market for the LungFit PH system.
• The $1 million milestone payment provides immediate financial benefit to Beyond Air.
• The ongoing royalty payments from Getz Healthcare will provide a recurring revenue stream.
• The LungFit PH system is environmentally friendly, reducing carbon footprint by eliminating the need for gas cylinders.
• The device is designed to be easy to use, with a filter that lasts 12 hours and is quick to replace.
• The device is approved for a wide range of patients from newborn infants to adolescents.

Risks

• The document mentions that forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.
• Risks include the ability to raise additional capital, the timing and results of future clinical trials, and regulatory approvals.
• There is also risk related to competition from others using similar technology and others developing products for similar uses.

Future Outlook

Beyond Air anticipates initiating shipments to Getz Healthcare and other international partners in 2025 and is advancing other LungFit systems for severe lung infections and neurological disorders.

Management Comments

• Steve Lisi, Chairman and Chief Executive Officer of Beyond Air, stated, 'We are thrilled to announce CE mark for LungFit PH, paving the way for commercial sales in Europe and other global regions.'
• Steve Lisi also mentioned, 'I am incredibly proud of the team that made this happen over the past 30 months and look forward to initiating shipments to our Asia-Pacific partner, Getz Healthcare, and other international partners in 2025.'

Industry Context

The approval of the LungFit PH system aligns with the growing demand for innovative and sustainable healthcare solutions, particularly in respiratory care. The device's ability to generate nitric oxide from ambient air addresses the logistical challenges associated with traditional nitric oxide delivery systems.

Comparison to Industry Standards

• The LungFit PH system's ability to generate nitric oxide on-demand from ambient air is a significant advancement compared to traditional cylinder-based systems used by companies like Linde and Air Liquide.
• The device's energy efficiency, using power equivalent to a 60-watt light bulb, is a notable improvement over the energy-intensive processes associated with traditional nitric oxide production.
• The LungFit PH system's indication for a wide range of patients, from newborn infants to adolescents, is comparable to other nitric oxide delivery systems but with the added benefit of on-demand generation.
• The device's ability to deliver nitric oxide at a dosage of 0.5 ppm to 80 ppm is consistent with the current standard of care for nitric oxide delivery, similar to systems offered by companies like Mallinckrodt.

Stakeholder Impact

• Shareholders will benefit from the positive news and the potential for increased revenue.
• Employees will be motivated by the company's progress and the successful launch of the LungFit PH system.
• Patients will have access to a new and innovative treatment option for respiratory conditions.
• Hospitals will benefit from the sustainable and efficient design of the LungFit PH system.

Next Steps

• Beyond Air will initiate shipments of the LungFit PH system to Getz Healthcare and other international partners in 2025.
• The company will continue to advance its other LungFit systems for the treatment of severe lung infections and neurological disorders.

Key Dates

Keywords

LungFit PH, CE Mark, Nitric Oxide, Hypoxic Respiratory Failure, Pulmonary Hypertension, Medical Device, Getz Healthcare, Ionizer Technology, Neonatal Care, Ventilator